Brokerages Set Envista Holdings Co. (NYSE:NVST) Price Target at $20.65

Envista Holdings Co. (NYSE:NVST) has earned an average recommendation of “Hold” from the fifteen ratings firms that are currently covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and three have assigned a buy rating to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $20.21.

NVST has been the subject of a number of research reports. Mizuho initiated coverage on Envista in a report on Wednesday, December 4th. They set an “underperform” rating and a $20.00 price objective for the company. Leerink Partners raised shares of Envista from an “underperform” rating to a “market perform” rating and raised their price target for the stock from $16.00 to $23.00 in a research note on Thursday, October 31st. Wells Fargo & Company assumed coverage on shares of Envista in a research report on Tuesday, October 8th. They issued an “equal weight” rating and a $20.00 price objective on the stock. Stifel Nicolaus raised their target price on shares of Envista from $18.00 to $21.00 and gave the company a “buy” rating in a research report on Wednesday, October 23rd. Finally, Robert W. Baird boosted their price target on shares of Envista from $17.00 to $22.00 and gave the stock a “neutral” rating in a research report on Thursday, October 31st.

Envista Stock Down 0.4 %

Shares of NYSE:NVST opened at $19.03 on Monday. The company has a 50 day moving average price of $20.25 and a two-hundred day moving average price of $18.52. The company has a market capitalization of $3.28 billion, a PE ratio of -2.45, a PEG ratio of 2.71 and a beta of 1.33. Envista has a 52 week low of $15.15 and a 52 week high of $25.64. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.77 and a current ratio of 2.08.

Envista (NYSE:NVST) last announced its quarterly earnings results on Wednesday, October 30th. The company reported $0.12 earnings per share for the quarter, beating analysts’ consensus estimates of $0.09 by $0.03. The firm had revenue of $601.00 million for the quarter, compared to analyst estimates of $590.34 million. Envista had a negative net margin of 53.42% and a positive return on equity of 3.76%. The business’s revenue was down 4.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.43 earnings per share. Analysts forecast that Envista will post 0.72 earnings per share for the current year.

Hedge Funds Weigh In On Envista

Institutional investors and hedge funds have recently modified their holdings of the stock. Bank of New York Mellon Corp lifted its holdings in Envista by 7.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 1,772,262 shares of the company’s stock worth $29,473,000 after purchasing an additional 127,421 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Envista by 13.0% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 35,737 shares of the company’s stock valued at $594,000 after acquiring an additional 4,121 shares during the period. Signaturefd LLC grew its stake in shares of Envista by 85.9% in the second quarter. Signaturefd LLC now owns 5,345 shares of the company’s stock valued at $89,000 after acquiring an additional 2,470 shares in the last quarter. Hantz Financial Services Inc. bought a new position in Envista during the second quarter worth about $1,144,000. Finally, Natixis Advisors LLC raised its stake in Envista by 3.6% in the 2nd quarter. Natixis Advisors LLC now owns 86,108 shares of the company’s stock worth $1,432,000 after purchasing an additional 2,958 shares in the last quarter.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.